Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Catheter Ablation Vs. Standard Medical Therapy — a Systematic Review and Meta-Analysis Publisher Pubmed



Mahalleh M1, 2 ; Soleimani H1 ; Pazoki M1 ; Maleki S1 ; Dastjerdi P1 ; Ebrahimi P1 ; Zafarmandi S1 ; Khamene SS1 ; Khawajah IM1 ; Tabassum S3 ; Bhardwaj R4 ; Mattumpuram J5 ; Kaplan A6 ; Vaseghi M7 Show All Authors
Authors
  1. Mahalleh M1, 2
  2. Soleimani H1
  3. Pazoki M1
  4. Maleki S1
  5. Dastjerdi P1
  6. Ebrahimi P1
  7. Zafarmandi S1
  8. Khamene SS1
  9. Khawajah IM1
  10. Tabassum S3
  11. Bhardwaj R4
  12. Mattumpuram J5
  13. Kaplan A6
  14. Vaseghi M7
  15. Seilani P1
  16. Bozorgi A1
  17. Hosseini K1
  18. Tzeis S8

Source: Heart Failure Reviews Published:2025


Abstract

Background: The latest guidelines advocate for catheter ablation (CA) over standard medical therapy (SMT) for managing atrial fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF). However, significant knowledge gaps exist regarding the effectiveness of CA vs. SMT in patients with heart failure with preserved ejection fraction (HFpEF). Methods: PubMed, Scopus, and Embase until February 2024 were systematically searched. Given the limited number of randomized studies, propensity score-matched observational studies comparing CA with SMT in AF patients with HFpEF were also included. The primary outcome was a composite endpoint of all-cause mortality and HF hospitalization. Results: Eight studies that enrolled 17,717 SMT and 2537 CA patients were included. CA was associated with a significantly lower risk of the composite endpoint of all-cause mortality and HF hospitalization (HR 0.61; 95% CI, 0.43–0.85). The risk of HF hospitalization (HR 0.44; 95% CI, 0.23–0.83), cardiovascular mortality (HR 0.43; 95% CI, 0.22–0.84), and AF recurrence (HR 0.53; 95% CI, 0.39–0.73) were also lower in the CA group. Conclusion: CA demonstrated significant cardiovascular morbidity and mortality benefits compared to SMT in the HFpEF population. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
Other Related Docs